Sandoz plans to build a Biosimilar Technical Development Center in Slovenia
Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026
Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026
Deal includes DTx-1252, a potential therapy for the neuromuscular disorder Charcot-Marie-Tooth disease type 1A (CMT1A), and two additional preclinical programs for other neuroscience indications
Long COVID is a debilitating chronic condition that has affected over 100 million people globally
OncoVeryx-F, a proprietary test developed by PredOmix, is set to transform early-stage cancer detection
Moist wound dressing for chronic wound treatment now available in Germany
Evonik specializes in mid- to large-scale, later clinical phase HPAPIs
The collaboration between CARER and Wholeleaf aims to offer an integrated approach to cancer patients, combining services and products to optimize their well-being
The programme was conducted as a part of MPMCx, an exclusive management programme for MBBS doctors by IIM-Ahmedabad in collaboration with DailyRounds
Subscribe To Our Newsletter & Stay Updated